The most common side effects are [[Arthralgia|joint]] and [[Myalgia|muscle pain]] in the arms or legs.<ref name="EMEA" /> There is an increased risk of [[infection]]s such as [[cellulitis]], [[hypocalcemia]] (low blood calcium), hypersensitivity allergy reactions, and [[osteonecrosis of the jaw]] and atypical [[femur fracture]]s.<ref name="EMEA" /><ref name="AustriaCodex" />  Another trial showed significantly increased rates of [[eczema]] and [[Inpatient care|hospitalization]] due to infections of the skin.<ref name="Cummings">{{cite journal |doi=10.1056/NEJMoa0809493 |title=Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis |year=2009 |last1=Cummings |first1=Steven R. |last2=Martin |first2=Javier San |last3=McClung |first3=Michael R. |last4=Siris |first4=Ethel S. |last5=Eastell |first5=Richard |last6=Reid |first6=Ian R. |last7=Delmas |first7=Pierre |last8=Zoog |first8=Holly B. |last9=Austin |first9=Matt |last10=Wang |first10=Andrea |last11=Kutilek |first11=Stepan |last12=Adami |first12=Silvano |last13=Zanchetta |first13=Jose |last14=Libanati |first14=Cesar |last15=Siddhanti |first15=Suresh |last16=Christiansen |first16=Claus |last17=Freedom |first17=Trial |journal=N Engl J Med |volume=361 |issue=8 |pages=756–65 |pmid=19671655|display-authors=8 }}</ref> It has been proposed that the increase in infections under denosumab treatment might be connected to the role of RANKL in the [[immune system]].<ref>{{cite journal|doi=10.1056/NEJMe0905480|last=Khosla|first=S|title=Increasing options for the treatment of osteoporosis|journal=N Engl J Med|year=2009|volume=361|issue=8|pages=818–820|pmid=19671654}}</ref> RANKL is expressed by [[T helper cells]], and is thought to be involved in [[dendritic cell]] maturation.<ref>{{EntrezGene|8600}} TNFSF11 tumor necrosis factor (ligand) superfamily, member 11; Homo sapiens {{quote|also known as ''RANKL''. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response.}}</ref>

 

